- Home
- CRMD vs DNA Comparison
CRMD vs DNA Comparison
Compare CRMD & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- DNA
- Stock Information
- Founded
- CRMD 2006
- DNA 2008
- Country
- CRMD United States
- DNA United States
- Employees
- CRMD N/A
- DNA N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRMD Health Care
- DNA Health Care
- Exchange
- CRMD Nasdaq
- DNA Nasdaq
- Market Cap
- CRMD 464.7M
- DNA 466.4M
- IPO Year
- CRMD 2010
- DNA N/A
- Fundamental
- Price
- CRMD $11.63
- DNA $8.11
- Analyst Decision
- CRMD Strong Buy
- DNA Sell
- Analyst Count
- CRMD 6
- DNA 5
- Target Price
- CRMD $15.00
- DNA $17.25
- AVG Volume (30 Days)
- CRMD 2.3M
- DNA 1.1M
- Earning Date
- CRMD 05-06-2025
- DNA 05-06-2025
- Dividend Yield
- CRMD N/A
- DNA N/A
- EPS Growth
- CRMD N/A
- DNA N/A
- EPS
- CRMD 0.28
- DNA N/A
- Revenue
- CRMD $82,553,827.00
- DNA $237,417,000.00
- Revenue This Year
- CRMD $207.65
- DNA N/A
- Revenue Next Year
- CRMD $50.13
- DNA $16.74
- P/E Ratio
- CRMD $41.90
- DNA N/A
- Revenue Growth
- CRMD N/A
- DNA 13.76
- 52 Week Low
- CRMD $3.61
- DNA $5.00
- 52 Week High
- CRMD $13.85
- DNA $38.60
- Technical
- Relative Strength Index (RSI)
- CRMD 69.76
- DNA 56.32
- Support Level
- CRMD $11.21
- DNA $6.42
- Resistance Level
- CRMD $12.31
- DNA $8.43
- Average True Range (ATR)
- CRMD 0.67
- DNA 0.60
- MACD
- CRMD 0.32
- DNA 0.11
- Stochastic Oscillator
- CRMD 82.29
- DNA 84.29
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.